Laureate signs antibody deal with Tolera
This article was originally published in Scrip
Laureate Pharma has signed a contract manufacturing agreement for Tolera Therapeutics' TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. TOL101 has demonstrated safety and efficacy in Phase I and II trails for treating episodes of rejection or as a means of preventing rejection in kidney and other solid organ transplants. Laureate, a biopharmaceutical development and protein production company, and Tolera, a biotechnology company, are both based in the US.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.